News | Radial Access | December 30, 2019

Merit Medical Announces its EVOlution in Radial Hemostasis in Europe

The product has FDA clearance in the U.S. and CE Mark approval in the EU for use in diagnostic cardiac catheterisation procedures and percutaneous coronary interventions

December 30, 2019 — Merit Medical Systems Inc., a leading manufacturer of proprietary devices used primarily in cardiology, radiology, oncology and endoscopy, announces the commercial launch of the PreludeSYNC EVO radial compression device in European, Middle Eastern and African markets.

The product has FDA clearance in the U.S. and CE Mark approval in the EU for use in diagnostic cardiac catheterisation procedures and percutaneous coronary interventions.

Merit’s PreludeSYNC EVO is a sterile, single-use, disposable device used to assist in gaining haemostasis of the arterial percutaneous access site following catheterisation procedures.

“PreludeSYNC EVO adds to our extensive line of radial compression devices that support PCI from start to finish. It was developed to meet the evolving clinical and health economic needs of physicians, administrators and cath lab teams around the globe. Our intent with PreludeSYNC EVO, the latest innovation in our premium cardiology product portfolio, is to provide physicians with even more procedural clarity and uniformity and their patients with safety and comfort,” said Fred P. Lampropoulos, Merit Medical’s Founder, Chairman, and Chief Executive Officer

The need for clarity and uniformity is fulfilled by PreludeSYNC EVO’s large clear window area with unobstructed site visibility. It is also optimised for diffuse and uniform balloon pressure. The safety features include a specialised connection and Slip-n-Lock cap which secures the syringe during inflation and deflation. A soft comfortable band, which is easy to secure, adjust and clean, is available in 24 and 29 cm sizes.

The PreludeSYNC EVO is immediately available in the EU, with registration coming in Middle East and Africa. 

For more information: www.merit.com

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...